Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

X
Trial Profile

Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metablok-Arch Biopartners (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Acronyms CS-AKI
  • Sponsors Arch Biopartners
  • Most Recent Events

    • 18 Jun 2024 According to an Arch Biopartners media release, the University of Calgarys Conjoint Health Research Ethics Board (CHREB) has approved the study
    • 16 Apr 2024 According to an Arch Biopartners media release, St. Michaels Hospital clinical team is awaiting ethics approval prior to beginning enrolment in the trial, The addition of St. Michaels as the third Canadian clinical site increases the number of trial sites to nine, with six hospitals in Turkey currently recruiting patients.
    • 16 Apr 2024 According to an Arch Biopartners media release, the company announced that a research team from St. Michaels Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top